Epigenetic control of NGAL also plays an important role in different diseases: miR-383 up-regulation suppresses psoriasis progression through inhibition of NGAL expression and disruption of NGAL-mediated JAK/STAT activation [57]; miR-181a-mediated down-regulation of NGAL, a known downstream effector molecule of the aldosterone–mineralocorticoid receptor (Aldo–MR) pathway, reduces cardiac stress due to Aldo-MR activation [58]; a computational analysis has revealed that miR-145-5p could be a target of NGAL in the regulation of EMT in bladder cancer [59]. The gene discussed is LCN2; the disease is psoriasis.